Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib in Recurrent, Platinum-Resistant Ovarian Cancer
NCT01853644Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jun 2013
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tivozanib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Northwestern University. Started Jun 2013; status: completed.
02
Drugs
tivozanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01853644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853644.